

Publications for Rosemary Balleine

2019

Moujaber, T., Etemadmoghadam, D., Kennedy, C., Chiew, Y., Balleine, R., Saunders, C., Wain, G., Gao, B., Hogg, R., Srirangan, S., Harnett, P., deFazio, A., et al (2019). BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. *American Society of Clinical Oncology Educational Book*.

2018

Gao, B., Lu, Y., Nieuweboer, A., Xu, H., Beesley, J., Boere, I., De Graan, A., de Bruijn, P., Gurney, H., Kennedy, C., Chiew, Y., Harnett, P., Balleine, R., deFazio, A., et al (2018). Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. *Scientific Reports*, 8(1), 1-10. [More Information]

Soon, P., Provan, P., Kim, E., Pathmanathan, N., Graham, D., Clarke, C., Balleine, R. (2018). Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study. *Clinical and Experimental Metastasis*, 35(1-2), 3-13. [More Information]

2016

Fox, P., Balleine, R., Lee, C., Gao, B., Balakrishnar, B., Menzies, A., Yeap, S., Ali, S., GebSKI, V., Provan, P., Liddle, C., Hui, R., Kefford, R., Wong, K., Wilcken, N., Gurney, H., et al (2016). Dose escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring - The TADE study. *Clinical Cancer Research*, 22(13), 3164-3171. [More Information]

Hollestelle, A., van der Baan, F., Berchuck, A., Johnatty, S., Aben, K., Agnarsson, B., Aittomaki, K., Alducci, E., Andrulis, I., Balleine, R., Carter, J., deFazio, A., et al (2016). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, 141(2), 386-401. [More Information]

Gao, B., Lindemann, K., Anderson, L., Fereday, S., Hung, J., Alsop, K., Tothill, R., GebSKI, V., Kennedy, C., Balleine, R., Harnett, P., deFazio, A., et al (2016). Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. *Gynecologic Oncology*, 142(3), 458-464. [More Information]

2015

Pirie, A., Guo, Q., Kraft, P., Canisius, S., Eccles, D., Rahman, N., Nevanlinna, H., Chen, C., Khan, S., Tyrer, J., Balleine, R., et al (2015). Common germline polymorphisms associated with breast cancer-specific survival. *Breast Cancer Research*, 17(1), 1-11. [More Information]

Guo, Q., Schmidt, M., Kraft, P., Canisius, S., Chen, C., Khan, S., Tyrer, J., Bolla, M., Wang, Q., Dennis, J., Balleine, R., et al (2015). Identification of novel genetic markers of breast cancer survival. *Journal of the National Cancer Institute*, 107(5), 1-9.

[More Information]

Mavaddat, N., Pharoah, P., Michailidou, K., Tyrer, J., Book, M., Bolla, M., Wang, Q., Dennis, J., Dunning, A., Shah, M., Balleine, R., Carpenter, J., Clarke, C., et al (2015). Prediction of breast cancer risk based on profiling with common genetic variants. *Journal of the National Cancer Institute*, 107(5), 1-15. [More Information]

2014

Purrington, K., Slettedahl, S., Bolla, M., Michailidou, K., Czene, K., Nevanlinna, H., Bojesen, S., Andrulis, I., Cox, A., Per, H., Clarke, C., Balleine, R., et al (2014). Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *Human Molecular Genetics*, 23(22), 6034-6046. [More Information]

Emmanuel, C., Chiew, Y., George, J., Etemadmoghadam, D., Anglesio, M., Sharma, R., Russell, P., Kennedy, C., Fereday, S., Hung, J., Hogg, R., Wain, G., Brand, A., Balleine, R., Clarke, C., Harnett, P., deFazio, A., et al (2014). Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. *Clinical Cancer Research*, 20(24), 6618-6630. [More Information]

Gao, B., Russell, A., Beesley, J., Chen, X., Healey, S., Henderson, M., Wong, K., Emmanuel, C., Galletta, L., Johnatty, S., Harnett, P., Balleine, R., deFazio, A., et al (2014). Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. *Scientific Reports*, 4, 1-9. [More Information]

Spurdle, A., Couch, F., Parsons, M., McGuffog, L., Barrowdale, D., Bolla, M., Wang, Q., Healey, S., Schmutzler, R., Balleine, R., Carpenter, J., Clarke, C. (2014). Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research*, 16(9), 1-16. [More Information]

Pathmanathan, N., Balleine, R., Jayasinghe, U., Stalgis-Bilinski, K., Provan, P., Byth Wilson, K., Bilous, M., Salisbury, E., Boyages, J. (2014). The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. *Journal of Clinical Pathology*, 67(3), 222-228. [More Information]

2013

Garcia-Closas, M., Couch, F., Lindstrom, S., Michailidou, K., Schmidt, M., Brook, M., Orr, N., Rhee, S., Riboli, E., Feigelson, H., Carpenter, J., Balleine, R., et al (2013). Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nature Genetics*, 45(4), 392-398. [More Information]

Pathmanathan, N., Balleine, R. (2013). Ki67 and proliferation in breast cancer. *Journal of Clinical Pathology*, 66(6), 512-516. [More Information]

Webster, L., Provan, P., Graham, J., Byth Wilson, K., Walker, R., Davis, S., Salisbury, E., Morey, A., Ward, R., Hawkins, N., Clarke, C., Balleine, R., et al (2013). Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33. *Pathology*, 45(7), 629-636. [More Information]

2012

Pathmanathan, N., Provan, P., Mahajan, H., Hall, G., Byth Wilson, K., Bilous, M., Balleine, R. (2012). Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing. *The Breast*, 21(6), 724-729. [More Information]

Khushi, M., Carpenter, J., Balleine, R., Clarke, C. (2012). Development of a data entry auditing protocol and quality assurance for a tissue bank database. *Cell and Tissue Banking*, 13(1), 9-13. [More Information]

Khushi, M., Carpenter, J., Balleine, R., Clarke, C. (2012). Electronic Biorepository Application System: Web-Based Software to Manage Receipt, Peer Review, and Approval of Researcher Applications. *Biopreservation and Biobanking*, 10(1), 37-44. [More Information]

Balleine, R., Wilcken, N. (2012). High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for Therapy. *Molecular Diagnosis and Therapy*, 16(4), 235-240. [More Information]

2011

Haiman, C., Chen, G., Vachon, C., Canzian, F., Dunning, A., Millikan, R., Wang, X., Ademuyiwa, F., Ahmed, S., Ambrosone, C., Balleine, R., Carpenter, J., Clarke, C., et al (2011). A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nature Genetics*, 43(12), 1210-1215. [More Information]

Stevens, K., Vachon, C., Lee, A., Slager, S., Lesnick, T., Oswald, C., Fasching, P., Miron, P., Carpenter, J., Clarke, C., Balleine, R., et al (2011). Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. *Cancer Research*, 71(19), 6240-6249. [More Information]

Emmanuel, C., Gava, N., Kennedy, C., Balleine, R., Sharma, R., Wain, G., Brand, A., Hogg, R., Etemadmoghadam, D., George, J., Clarke, C., Harnett, P., deFazio, A., et al (2011). Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. *PLoS One*, 6(3), e17617-1-e17617-18. [More Information]

Houssami, N., Macaskill, P., Balleine, R., Bilous, M., Pegram, M. (2011). HER2 discordance between primary breast cancer

and its paired metastasis: Tumor biology or test artefact? Insights through meta-analysis. *Breast Cancer Research and Treatment*, 129(3), 659-674. [More Information]

2010

Pathmanathan, N., Salisbury, E., Provan, P., Bilous, M., Byth Wilson, K., Milliken, J., Clarke, C., Balleine, R. (2010). A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breast. *Pathology*, 42(1), 28-36. [More Information]

Spurdle, A., Lakhani, S., Da Silva, L., Balleine, R., kConFab Investigators., Goldgar, D. (2010). Bayes Analysis Provides Evidence of Pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) Variants Displaying In Vitro Splicing Results of Equivocal Clinical Significance. *Human Mutation*, 31(2), E1141-E1145. [More Information]

Pathmanathan, N., Albertini, A., Provan, P., Milliken, J., Salisbury, E., Bilous, M., Byth Wilson, K., Balleine, R. (2010). Diagnostic evaluation of papillary lesions of the breast on core biopsy. *Modern Pathology*, 23(7), 1021-1028. [More Information]

Balleine, R., Provan, P., Pupo, G., Pathmanathan, N., Cummings, M., Farshid, G., Salisbury, E., Bilous, M., Byth Wilson, K., kConFab Investigators., Mann, G. (2010). Familial Concordance of Breast Cancer Pathology as an Indicator of Genotype in Multiple-Case Families. *Genes Chromosomes and Cancer*, 49(12), 1082-1094. [More Information]

Da Silva, L., Simpson, P., Smart, C., Cocciardi, S., Waddell, N., Lane, A., Morrison, B., Vargas, A., Healey, S., Beesley, J., Bilous, M., Balleine, R., et al (2010). HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. *Breast Cancer Research*, 12(4), R46-1-R46-12. [More Information]

2009

Graham, J., Mote, P., Salagame, U., Van Dijk, J., Balleine, R., Huschtscha-Holliday, L., Reddel, R., Clarke, C. (2009). DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. *Endocrinology*, 150(7), 3318-3326. [More Information]

Graham, J., Mote, P., Salagame, U., Balleine, R., Huschtscha-Holliday, L., Clarke, C. (2009). Hormone-Responsive Model of Primary Human Breast Epithelium. *Journal of Mammary Gland Biology and Neoplasia*, 14(4), 367-379. [More Information]

2008

Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. *Clinical Cancer Research*, 14(21), 6924-6932. <a href="http://dx.doi.org/10.1158/1078-0432.CCR-07-"

5189">[More Information]

Loughrey, M., Provan, P., Byth Wilson, K., kConFab Investigators., Balleine, R. (2008). Histopathological features of "BRCA1" familial breast cancers in the kConFab resource. *Pathology*, 40(4), 352-358. [More Information]

Balleine, R., Webster, L., Davis, S., Salisbury, E., Palazzo, J., Schwartz, G., Cornfield, D., Walker, R., Byth Wilson, K., Clarke, C., et al (2008). Molecular Grading of Ductal Carcinoma In situ of the Breast. *Clinical Cancer Research*, 14(24), 8244-8252. [More Information]

Balleine, R., Bilous, M., Morey, A. (2008). Painting by numbers: The power and peril of synoptic pathology reporting for cancer. *Asia-Pacific Journal of Clinical Oncology*, 4(2), 75-76.

Webster, L., Lee, S., Ringland, C., Morey, A., Hanby, A., Morgan, G., Byth Wilson, K., Mote, P., Provan, P., Ellis, I., Lamoury, G., Clarke, C., Balleine, R., et al (2008). Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. *Clinical Cancer Research*, 14(20), 6625-6633. [More Information]

2007

Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. *Clinical Pharmacology & Therapeutics*, 82(1), 33-40. [More Information]

2006

Mann, G., Thorne, H., Balleine, R., Butow, P., Clarke, C., Edkins, E., Evans, G., Fereday, S., Haan, E., Gattas, M., Kirk, J., Leary, J., Pupo, G., et al (2006). Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. *Breast Cancer Research*, 8(1), 1-15. [More Information]

Balleine, R., Murali, R., Bilous, A., Farshid, G., Waring, P., Provan, P., Byth, K., Thorne, H., KConFab, C., Kirk, J. (2006). Histopathological features of breast cancer in carriers of ATM gene variants. *Histopathology*, 49(5), 523-532. [More Information]

Balleine, R., Murali, R., Bilous, M., Farshid, G., Waring, P., Provan, P., Byth Wilson, K., Thorne, H., KConFab, C., Kirk, J. (2006). Histopathological features of breast cancer in carriers of ATM gene variants. *Histopathology*, 49. [More Information]

Farshid, G., Balleine, R., Cummings, M., Waring, P., The Kathleen Cunningham Consortium for Research into Familial Breast Cancer. (2006). Morphology of Breast Cancer as a Means of Triage of Patients for BRCA1 Genetic Testing. *American Journal of Surgical Pathology*, 30(11), 1357-1366. [More Information]

Guminski, A., Balleine, R., Chiew, Y., Webster, L., Tapner, M., Farrell, G., Harnett, P., deFazio, A. (2006). MRP2 (ABCC2)

and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. *Gynecologic Oncology*, 100(2), 239-246. [More Information]

WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. *Journal of Clinical Oncology*, 24(16), 2448-2455. [More Information]

2005

Wong, M., Evans, S., Rivory, L., Hoskins, J., Mann, G., Farlow, D., Clarke, C., Balleine, R., Gurney, H. (2005). Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. *Clinical Pharmacology & Therapeutics*, 77(1), 33-42. [More Information]

Webster, L., Bilous, M., Willis, L., Byth Wilson, K., Burgemeister, F., Salisbury, E., Clarke, C., Balleine, R. (2005). Histopathologic indicators of breast cancer biology: insights from population mammographic screening. *British Journal of Cancer*, 92(8), 1366-1371. [More Information]

Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. *International Journal of Cancer*, 117(6), 1049-54. [More Information]

2004

Wong, M., Balleine, R., Collins, M., Liddle, C., Clarke, C., Gurney, H. (2004). Cyp3A5 Genotype And Midazolam Clearance In Australian Patients Receiving Chemotherapy. *Pharmacology and Therapeutics*, 75(6), 529-538. [More Information]

Balleine, R., Earls, P., Webster, L., Mote, P., deFazio, A., Harnett, P., Clarke, C. (2004). Expression Of Progesterone Receptor A And B Isoforms In Low-Grade Endometrial Stromal Sarcoma. *International Journal of Gynecological Pathology*, 23(2), 138-144. [More Information]

2001

Balleine, R., Humphrey, K., Clarke, C. (2001). Tumour banks: providing human tissue for cancer research. *Medical Journal of Australia*, 175, 293-294.

2000

Mote, P., Balleine, R., McGowan, E., Clarke, C. (2000). Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. *Human Reproduction*, 15(supp3), 48-56.

Balleine, R., Schoenberg Fejzo, M., Sathasivam, P., Basset, P., Clarke, C., Byrne, J. (2000). The hD52 (TDP52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. *Genes Chromosomes*

